Genomic Evaluation of Clinically Ambiguous Pigmented Lesions

Area of Science:

• Dermatology
• Oncology
• Genomics

Background:

• Clinical evaluation of pigmented lesions is critical due to the fatal potential of missed melanomas.
• Ambiguous pigmented lesions (APLs) present a diagnostic challenge, often requiring clinical follow-up.
• Traditional visual assessment has limitations in definitively ruling out melanoma in APLs.

Purpose of the Study:

• To evaluate the prevalence of APLs in clinical practice.
• To assess the utility of non-invasive genomic testing in differentiating melanomas within APLs.
• To improve diagnostic accuracy and biopsy decisions for clinically indeterminate pigmented lesions.

Main Methods:

• An informal survey assessed dermatology providers' ability to identify melanomas among APL images.
• A retrospective chart review analyzed 1,254 APLs evaluated with non-invasive genomic testing.
• Lesions included in the review were initially below the standard biopsy threshold.

Main Results:

• 6 out of 8 dermatology providers incorrectly identified melanomas in a visual assessment of APLs.
• Non-invasive genomic testing identified 35 melanomas among 1,254 APLs.
• All identified melanomas were initially considered below the biopsy threshold.

Conclusions:

• Non-invasive genomic testing significantly enhances the diagnostic capability for APLs.
• This technology can refine biopsy decisions, particularly for clinically indeterminate pigmented lesions.
• Genomic testing offers a valuable tool to reduce the risk of missed melanoma diagnoses in challenging cases.